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Abstract 
Using US cancer registry data of SEER (Surveillance, Epidemiology, and End Results 
Program), data based analyses of prevalence, incidence, and survival rates are able for 
the medical risk assessment in life insurance. Statistical analyses of cancer patients 
and base population were performed using SEER*Stat from the US National Cancer 
Institute. The system provides multivariate restrictions of patient groups and 
subdivisions of outcomes. The lecture focuses on survival time analyses and additional 
calculations for the outcome of extra mortality rates of cancer patients in relation to 
base population. Based on these extra mortality rates, principles of underwriting 
decisions in life insurance will be presented.  
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